Gilead Sciences, Inc.
NEWS
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
Researchers with the Georgia Institute of Technology recently published work that describes several new approaches to improving CAR-T, particularly for solid tumors.
The Phase II study showed that the asset achieved antiviral activity in healthy patients and set the stage for AT-527’s potential as a preventative treatment for COVID following exposure to the virus.
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
As Gilead gets ready to open its doors to its new operations site in North Carolina, the company reported its product sales for the second quarter increased 21% year-over-year primarily driven by Veklury.
JOBS
IN THE PRESS